DCT

3:26-cv-08720

AstraZeneca Pharma LP v. Cipla Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-08720, D.N.J., 07/14/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Cipla USA, Inc. has a principal place of business in the district, has allegedly committed acts of infringement there, and has consented to venue in related actions. Defendant Cipla Limited, as a foreign corporation, may be sued in any district where it is subject to personal jurisdiction.
  • Core Dispute: Plaintiffs allege that Defendants' Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug LYNPARZA® (olaparib) infringes four U.S. patents covering the drug's formulation and method of use.
  • Technical Context: The dispute centers on olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, a class of targeted therapies used for treating cancers with specific DNA repair deficiencies, such as certain ovarian, breast, and prostate cancers.
  • Key Procedural History: The complaint notes that this action is related to other pending litigation in the same district between the same parties. Those suits concern Defendants' earlier ANDA (No. 219410) for lower-dose (100 and 150 mg) generic olaparib tablets, while the present action concerns a new ANDA (No. 221232) for higher-dose (200 mg, 250 mg, and 300 mg) tablets.

Case Timeline

Date Event
2003-07-25 '562 Patent Priority Date
2008-10-07 '001, '695, '810 Patents Priority Date
2014-10-14 U.S. Patent 8,859,562 Issues
2024-05-07 U.S. Patent 11,975,001 Issues
2024-05-21 Defendants notify Plaintiffs of prior ANDA (No. 219410)
2024-07-30 U.S. Patent 12,048,695 Issues
2024-11-19 U.S. Patent 12,144,810 Issues
2026-06-11 Defendants notify Plaintiffs of ANDA No. 221232
2026-07-14 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,859,562 - "Use of RNAi Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer"

  • Patent Identification: U.S. Patent No. 8,859,562, issued October 14, 2014 (the "'562 Patent").

The Invention Explained

  • Problem Addressed: The patent addresses the need for a cancer treatment that is both effective and selective, particularly for cancers with specific genetic vulnerabilities, to avoid the side effects associated with conventional chemotherapy and radiotherapy that harm healthy cells '562 Patent, col. 2:1-8
  • The Patented Solution: The invention describes a method of treating cancers that are defective in homologous recombination (HR), a key DNA repair pathway '562 Patent, col. 1:4-8 By inhibiting a different DNA repair enzyme, poly(ADP-ribose) polymerase (PARP), the cancer cells lose their remaining ability to repair DNA damage and die, a concept known as synthetic lethality. This method selectively kills cancer cells with HR defects (e.g., those with BRCA1/2 mutations) while largely sparing normal cells that have a functional HR pathway '562 Patent, abstract '562 Patent, col. 2:9-15
  • Technical Importance: The invention embodies the principle of synthetic lethality, which represented a significant advance in targeted oncology by exploiting a cancer's specific genetic weaknesses for selective cell killing.

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶¶39, 41
  • Essential elements of independent claim 1 include:
    • A method of treatment of cancer cells defective in homologous recombination (HR).
    • Identifying a human patient with a familial predisposition to gene-linked hereditary cancer, wherein said cancer comprises cells defective in HR.
    • Identifying a compound which inhibits PARP-1.
    • Administering a therapeutically effective amount of the compound to the patient.

U.S. Patent No. 11,975,001 - "Immediate Release Pharmaceutical Formulation of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One"

  • Patent Identification: U.S. Patent No. 11,975,001, issued May 7, 2024 (the "'001 Patent").

The Invention Explained

  • Problem Addressed: The patent's background explains that the active pharmaceutical ingredient, olaparib (also called Compound 1), has poor aqueous solubility and moderate permeability, which can lead to poor bioavailability when formulated as a conventional immediate-release (IR) tablet '001 Patent, col. 2:31-41 '001 Patent, col. 3:9-14 This makes it difficult to deliver a sufficient therapeutic dose orally in a manageable number of pills.
  • The Patented Solution: The invention is a pharmaceutical formulation that improves olaparib's bioavailability and allows for higher drug loading. It achieves this by creating a "solid dispersion" of the drug within a matrix polymer, such as copovidone, that has low hygroscopicity and a high softening temperature '001 Patent, abstract '001 Patent, col. 3:51-4:21 This formulation helps keep the drug in a more soluble (amorphous) state, enhancing its absorption in the gastrointestinal tract '001 Patent, col. 9:30-44
  • Technical Importance: This technology provides a viable method for orally administering high doses of a poorly soluble drug, which is a common and significant challenge in pharmaceutical development.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶¶56, 60-61
  • Essential elements of independent claim 1 include:
    • An immediate-release pharmaceutical composition.
    • Comprising a solid dispersion which includes:
      • 100 mg to 200 mg of olaparib.
      • At least one polymer from a specified list (e.g., copovidone, povidone, etc.).
    • The weight ratio of olaparib to the polymer is in the range of 1:1 to 1:9.
    • The total concentration of olaparib in the solid dispersion is from 10% to 50% by weight.

U.S. Patent No. 12,048,695 - "Immediate Release Pharmaceutical Formulation of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One"

  • Patent Identification: U.S. Patent No. 12,048,695, issued July 30, 2024 (the "'695 Patent") Compl. ¶71

Technology Synopsis

  • The patent relates to an immediate-release pharmaceutical composition of olaparib formulated as a solid dispersion. The complaint specifies that the patent claims a composition that meets certain "stability testing parameters," suggesting a focus on ensuring the formulation remains stable over time Compl. ¶73
  • Asserted Claims: The complaint asserts at least claim 1 Compl. ¶79
  • Accused Features: The accused features are Defendants' generic olaparib tablets Compl. ¶79

U.S. Patent No. 12,144,810 - "Immediate Release Pharmaceutical Formulation of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One"

  • Patent Identification: U.S. Patent No. 12,144,810, issued November 19, 2024 (the "'810 Patent") Compl. ¶90

Technology Synopsis

  • The patent claims an immediate-release pharmaceutical composition of olaparib in the form of a solid dispersion with certain excipients Compl. ¶92 This suggests a focus on the specific combination of the active drug and other inactive ingredients in the formulation.
  • Asserted Claims: The complaint asserts at least claim 1 Compl. ¶98
  • Accused Features: The accused features are Defendants' generic olaparib tablets Compl. ¶98

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendants' ANDA Product, which are generic olaparib tablets in 200 mg, 250 mg, and 300 mg strengths, for which Defendants seek FDA approval under ANDA No. 221232 Compl. ¶2 Compl. ¶31
  • Functionality and Market Context: The accused product is a generic version of Plaintiffs' LYNPARZA® tablets and is intended for the same medical indications: treating certain types of ovarian, breast, pancreatic, and prostate cancer Compl. ¶30 Compl. ¶31 As a PARP inhibitor, its function is to block a DNA repair pathway in cancer cells Compl. ¶30 The filing of the ANDA itself, seeking approval to market this generic product before the expiration of the patents-in-suit, constitutes the alleged act of infringement under the Hatch-Waxman Act Compl. ¶1 Compl. ¶40

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

U.S. Patent 8,859,562 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treatment of cancer cells defective in homologous recombination (HR) The proposed labeling for the ANDA Product allegedly directs the use of generic olaparib for treating cancers, including those known to have HR defects. ¶30; ¶41 col. 2:5-9
identifying a human patient with a familial predisposition to gene-linked hereditary cancer, wherein said cancer comprises cancer cells defective in homologous recombination The proposed labeling allegedly instructs use in patient populations with cancers associated with hereditary HR defects (e.g., BRCA mutations). ¶30; ¶41 col. 1:40-45
administering to said human patient a therapeutically effective amount of said compound The proposed labeling will allegedly direct administration of the ANDA Product to patients for the approved indications. ¶41; ¶43 col. 2:13-15

U.S. Patent 11,975,001 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
An immediate-release pharmaceutical composition The ANDA Product is allegedly an immediate-release tablet formulation. ¶31; ¶54 col. 3:51-54
comprising a solid dispersion The ANDA Product is allegedly a generic version of LYNPARZA®, which the complaint asserts is a solid dispersion formulation. ¶31; ¶54 col. 3:51-4:21
(i) 100 mg to 200 mg of...[olaparib] The ANDA Product includes 200 mg, 250 mg, and 300 mg dosage strengths. The 200 mg strength falls within the claimed range of "100 mg to 200 mg", although claim 1 of the '001 patent does not encompass the 250mg and 300mg doses. ¶31 col. 13:1-13
(ii) at least one polymer chosen from copovidone, povidone, hypromellose phthalate... The ANDA Product, as a generic equivalent to LYNPARZA®, is alleged to contain a polymer from the claimed list to form the solid dispersion. ¶54; ¶60 col. 5:1-14
wherein the weight ratio of Compound 1 to the at least one polymer...is in the range of from 1:1 to 1:9 The ANDA Product is alleged to have a drug-to-polymer ratio that meets this limitation. ¶54; ¶60 col. 6:62-67
  • Identified Points of Contention:
    • Scope Questions: For the '562 Patent, a central question will be whether the instructions in the proposed label for the ANDA Product direct or encourage a method of use that falls within the scope of the claims. For the '001 Patent, it raises the question of whether the 250 mg and 300 mg dosage strengths, which are outside the express "100 mg to 200 mg" limitation of claim 1, could be alleged to infringe other claims or under the doctrine of equivalents.
    • Technical Questions: For the '001, '695, and '810 Patents, the analysis will turn on the specific technical details of the ANDA Product's formulation. Key questions will involve whether the generic product uses the same polymer, drug-to-polymer ratio, and drug concentration as required by the claims, and whether it meets any claimed stability parameters. The complaint alleges infringement "either literally or under the doctrine of equivalents," suggesting that direct identity may be a point of dispute Compl. ¶60

V. Key Claim Terms for Construction

  • Term from the '562 Patent: "defective in homologous recombination (HR)"

    • Context and Importance: This term defines the patient population for the method of treatment. Its construction is critical to determining the scope of infringement, as it dictates what types of cancers and patients are covered by the patented method. Practitioners may focus on whether this term requires a specific genetic test or if it can be defined by broader cellular characteristics.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a non-exhaustive list of genes involved in the HR pathway, including ATM, ATR, RAD51, and many others beyond just BRCA1 and BRCA2, suggesting the term is not limited to a specific genetic mutation '562 Patent, col. 2:2-12
      • Evidence for a Narrower Interpretation: The background focuses heavily on BRCA1 and BRCA2 as the primary examples of genes linked to HR-defective cancers '562 Patent, col. 1:50-67 A party might argue that the invention is principally directed to these well-known mutations, suggesting a narrower scope.

  • Term from the '001 Patent: "solid dispersion"

    • Context and Importance: This term defines the core formulation technology. Its construction will determine whether Defendants' formulation technique falls within the claims. Practitioners may focus on whether the term requires the drug to be in a fully amorphous or molecularly dispersed state, versus a broader definition that could include nanocrystalline domains.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent provides a general definition: "systems in which an active agent is dispersed in an excipient carrier," and explicitly states that this can include "discrete domains of crystalline or amorphous drug" '001 Patent, col. 7:63-8:2
      • Evidence for a Narrower Interpretation: The patent repeatedly emphasizes the advantages of achieving an amorphous form to improve solubility and bioavailability '001 Patent, col. 9:30-44 A party could argue that the true inventive concept is the stable amorphous dispersion, and the term should be construed to require a substantially amorphous, not crystalline, state.

VI. Other Allegations

  • Indirect Infringement: Plaintiffs allege that Defendants will induce infringement of all four patents through their proposed product labeling, which will allegedly instruct and encourage physicians and patients to use the generic product in an infringing manner Compl. ¶¶43, 62, 81, 100 Plaintiffs also allege contributory infringement, stating the ANDA Product is especially made for infringing use and is not suitable for substantial non-infringing use Compl. ¶¶44, 63, 82, 101
  • Willful Infringement: Plaintiffs allege that Defendants have acted with full knowledge of the patents-in-suit, citing the Paragraph IV certification letter dated June 11, 2026, as evidence of pre-suit knowledge Compl. ¶2 Compl. ¶33 The complaint asserts that Defendants proceeded without a reasonable basis for believing they would not be liable, forming the basis for a willfulness claim Compl. ¶¶46, 65, 84, 103

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of compositional infringement: does the specific formulation of Defendants' generic olaparib product-including its polymer, excipients, drug-to-polymer ratio, and stability profile-fall within the literal scope of the claims of the '001, '695, and '810 patents? Given the complexity of pharmaceutical formulations, this will likely be a central point of technical and legal dispute, potentially hinging on the doctrine of equivalents.
  • A second key issue concerns induced infringement of the method of use: will the FDA-approved label for Defendants' product contain language that instructs or encourages its use in a manner that directly aligns with the steps recited in claim 1 of the '562 patent, particularly the identification of patients with cancers defective in homologous recombination?
  • Finally, the case will almost certainly involve a significant challenge to the validity of the patents-in-suit. A crucial question for the court will be whether the claimed inventions-both the therapeutic method of the '562 patent and the specific solid dispersion formulations of the other patents-were non-obvious and novel over the prior art at the time of their respective priority dates.
Loading Complaint